

14 - References

References

496 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 4 optimised11 and clozapine may be considered. However, there is insufficient evidence to recommend the use of any one antipsychotic medication over another in AUD. Antipsychotics do not improve AUD itself.⁵¹

References

1. Gov.UK Department of Health and Social Care. UK Chief Medical Officers' low risk drinking guidelines. 2016 (last accessed August 2024); <https://www.gov.uk/government/publications/alcohol-consumption-advice-on-low-risk--drinking>.
2. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence. Clinical guideline [CG115]. 2011 (last checked July 2019, last accessed August 2024); <https://www.nice.org.uk/guidance/cg115>.
3. National Institute for Health and Care Excellence. Alcohol-use disorders: prevention. Public health guideline [PH24]. 2010 (last checked July 2019, last accessed August 2024; updated 2010). <https://www.nice.org.uk/guidance/ph24>.
4. Babor T, et al. AUDIT: The Alcohol Use Disorders Identification Test Guidelines for Use in Primary Care, 2nd edn. 2001; <https://iris.who.int/handle/10665/67205>.
5. Stockwell T, et al. The severity of alcohol dependence questionnaire: its use, reliability and validity. *Br J Addict* 1983; 78:145–155.
6. Minozzi S, et al. Anticonvulsants for alcohol withdrawal. *Cochrane Database Syst Rev* 2010; 3:CD005064.
7. Amato L, et al. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. *Cochrane Database Syst Rev* 2011; 6:CD008537.
8. Brathen G, et al. EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. *Eur J Neurol* 2005; 12:575–581.
9. Lingford-Hughes AR, et al. Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. *J Psychopharmacol* 2012; 26:899–952.
10. NSW Government. Clinical guidance for withdrawal from alcohol and other drugs. 2023 (last accessed August 2024); <https://www.health.nsw.gov.au/aod/professionals/Pages/clinical-guidance.aspx>.
11. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). *N Engl J Med* 2014; 371:2109–2113.

12. Sullivan JT, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). *Br J Addict* 1989; 84:1353-1357.
13. Gossop M, et al. A Short Alcohol Withdrawal Scale (SAWS): development and psychometric properties. *Addict Biol* 2002; 7:37-43.
14. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis and management of physical complications. Clinical guideline [CG100]. 2010 (last updated April 2017, last accessed August 2024); <https://www.nice.org.uk/guidance/cg100>.
15. Bahji A, et al. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. *Addiction* 2022; 117:2591-2601.
16. Fluyau D, et al. Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management. *Eur J Clin Pharmacol* 2023; 79:1147-1157.
17. Thomson AD, et al. Time to act on the inadequate management of Wernicke's encephalopathy in the UK. *Alcohol Alcohol* 2013; 48:4-8.
18. Thomson AD, et al. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and emergency department. *Alcohol Alcohol* 2002; 37:513-521.
19. Day E, et al. Thiamine for prevention and treatment of Wernicke-Korsakoff syndrome in people who abuse alcohol. *Cochrane Database Syst Rev* 2013; 7:CD004033.
20. National Institute for Health and Care Excellence. CKS: Alcohol - problem drinking: supporting evidence. 2023 (last accessed September 2024); <https://cks.nice.org.uk/topics/alcohol-problem-drinking/supporting-evidence>.
21. Burnette EM, et al. Novel agents for the pharmacological treatment of alcohol use disorder. *Drugs* 2022; 82:251-274.
22. Köhne S, et al. Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. *Expert Opin Emerg Drugs* 2024; 29:219-232.
23. Rösner S, et al. Acamprosate for alcohol dependence. *Cochrane Database Syst Rev* 2010; 9:CD004332.
24. Rösner S, et al. Opioid antagonists for alcohol dependence. *Cochrane Database Syst Rev* 2010; 12:CD001867.
25. AOP Orphan Ltd. Summary of product characteristics. Adepend (naltrexone hydrochloride) 50mg filmcoated tablets. 2020 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/3559/smpc>.
26. Leighty AE, et al. Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans. *Ment Health Clin* 2019; 9:392-396.
27. Krupitsky E, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. *Addiction* 2013; 108:1628-1637.
28. Soyka M, et al. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis. *Pharmacopsychiatry* 2016; 49:66-75.
29. Palpacuer C, et al. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. *PLoS Med* 2015; 12:e1001924.
30. Kotake K, et al. Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: a

systematic review and network meta-analysis. *Addiction* 2024; 119:815–832.

31. Mutschler J, et al. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. *Pharmacopsychiatry* 2016; 49:137–141.

Addictions and substance misuse CHAPTER 4 32. Bahji A, et al. Pharmacotherapies for adults with alcohol use disorders: a systematic review and network meta-analysis. *J Addict Med* 2022; 16:630–638. 33. Agabio R, et al. Baclofen for alcohol use disorder. *Cochrane Database Syst Rev* 2023; 1:CD012557. 34. Pani PP, et al. Anticonvulsants for alcohol dependence. *Cochrane Database Syst Rev* 2014; 2014:CD008544. 35. Votaw VR, et al. An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial. *Addiction* 2023; 118:1040–1052. 36. Morley KC, et al. Topiramate versus naltrexone for alcohol use disorder: a genotype-stratified double-blind randomized controlled trial. *Am J Psychiatry* 2024; 181:403–411. 37. Kranzler HR, et al. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. *Addiction* 2019; 114:1547–1555. 38. UK Teratology Information Service (UKTIS). 2024; www.UKTIS.org. 39. O'Malley SS, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. *J Clin Psychiatry* 2015; 76:e207–e213. 40. Miranda R, et al. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. *Addict Biol* 2014; 19:941–954. 41. Roos CR, et al. Reward drinking and naltrexone treatment response among young adult heavy drinkers. *Addiction* 2021; 116:2360–2371. 42. Joshi P, et al. Evaluation and management of alcohol use disorder among older adults. *Curr Geriatr Rep* 2021; 10:82–90. 43. Gudin JA, et al. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. *Postgrad Med* 2013; 125:115–130. 44. Pettinati HM, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. *J Subst Abuse Treat* 2008; 34:378–390. 45. Kampman KM, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. *Drug Alcohol Depend* 2013; 133:94–99. 46. Public Health England. Better care for people with co-occurring mental health and alcohol/drug use conditions. A guide for commissioners and service providers. 2017; https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/625809/Co-occurring_mental_health_and_alcohol_drug_use_conditions.pdf. 47. Agabio R, et al. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. *Cochrane Database Syst Rev* 2018; 4:CD008581. 48. Stokes PRA, et al. Pharmacological treatment of mood disorders and comorbid addictions: a systematic review and meta-analysis: *Traitement Pharmacologique des Troubles de L'humeur et des Dépendances Comorbides: une Revue Systématique et une Méta-Analyse*. *Can J Psychiatry* 2020; 65:749–769. 49. Di Nicola M, et al. Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: the role of extended-release trazodone. *Curr Neuropharmacol* 2023; 21:2195–2205. 50. Taylor D, et al. The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use. *Ther Adv Psychopharmacol* 2024; 14:20451253241243297. 51. Wood E, et al. Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. *CMAJ* 2023; 195:E1364–E1379. 52. Pettinati HM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. *Am J Psychiatry* 2010; 167:668–675. 53. Adamson SJ, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. *J Clin Psychopharmacol* 2015; 35:143–149. 54. Kelson M, et al. Ketamine treatment for alcohol use disorder: a systematic review. *Cureus* 2023; 15:e38498. 55. Stedman M, et al. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting

alcohol dependence. *Alcohol Clin Exp Res* 2010; 34:1822–1831. 56. Ipser JC, et al. Pharmacotherapy for anxiety and comorbid alcohol use disorders. *Cochrane Database Syst Rev* 2015; 1:CD007505. 57. Verplaetse TL, et al. Pharmacotherapy for co-occurring alcohol use disorder and post-traumatic stress disorder: targeting the opioidergic, noradrenergic, serotonergic, and GABAergic/glutamatergic systems. *Alcohol Res* 2018; 39:193–205. 58. Morice CK, et al. Comorbid alcohol use and post-traumatic stress disorders: pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents. *Prog Neuropsychopharmacol Biol Psychiatry* 2022; 115:110506. 59. Brown & Burk UK Ltd. Summary of product characteristics. Disulfiram 200mg tablets. 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/11168>.

Revision #1

Created 2026-01-04 20:16:02 UTC by Omar Ayman

Updated 2026-01-04 20:16:02 UTC by Omar Ayman